Summa Biotech is a medical biotech company that is founded in 2022 and focuses on developing ground-breaking RNA-based medicines that reverse the damage of ischemic heart disease, which is a leading cause of death worldwide.
We aim restore damaged heart tissue by eliciting the regeneration of healthy cells and tissues using RNA therapeutics.
Summa Biotech’s strategy is to develop game-changing curative therapies for ischemic heart disease by leveraging academic expertise, cutting-edge disease models and fostering a culture of team excellence.
Company Details
- Employees
- 5
- Founded
- 2022
- Address
- Klokkenbergweg 8, Amsterdam,north Holland 1101as,netherlands
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.summa-biotech.com
- HQ
- Amsterdam, North Holland
Summa Biotech Questions
Summa Biotech's website is http://www.summa-biotech.com
Summa Biotech's LinkedIn profile is https://nl.linkedin.com/company/summa-biotech
Summa Biotech has
5 employees.
View email and phone details for 5
employees at Summa Biotech.
Summa Biotech's industry is
Biotechnology Research
Summa Biotech's top competitors are
Cleara Biotech B.v.,
Pno Life Sciences & Health,
Regenerative Medicine Utrecht,
Sentryx,
Merus N.v.,
Pantarhei Bioscience B.v.,
Lava Therapeutics N.v.,
Scellgen,
Pepscope,
Amt Medical.
Summa Biotech's categories are Biotechnology Research
Summa Biotech's founding year is 2022
